Sym021 is a mAb that binds PD1 and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD1-mediated inhibition of the immune response.
Symphogen has six immuno-oncology product candidates under development with Servier, of which three are currently in Phase 1 trials (Sym021, Sym022 and Sym023). Sym024, Sym025 and Sym026 are in discovery phase against undisclosed cancer targets.
The Phase 1 trials are the first studies to test Sym021, Sym022 and Sym023 in humans. The primary purpose of these trials is to determine if Sym021, Sym022 and Sym023 are safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Clinical development of Sym021
Preclinical models have shown that combinations of Sym021, Sym022 and Sym023 provide better anti-tumor effects compared to each product candidate administered on its own. We intend to use these product candidates in a variety of doublet or triplet combinations and currently, two studies are ongoing
to investigate the combinations Sym021-Sym022 as well and Sym021- Sym023.
In addition, three Phase 1 trials with each of the antibodies are also in progress.
PD1, LAG3 and TIM3 are immune checkpoints playing important roles in regulating immune responses, including the body’s immune response to tumor cells.
Identifying I/O targets
Symphogen has proven its ability to deliver unique antibodies on aggressive timelines as exemplified with our filing of three INDs in six months – Sym021, Sym022 and Sym023. Such an exceptional achievement is made possible by the unique way we run projects. Developability assessment is an integrated part of
the lead selection process, which means that potential critical features of the lead candidates are taken into consideration very early in the development path.